Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.
Question: Should Hydroxychloroquine + Azithromycin vs Hydroxychloroquine be used for COVID-19 patients?
Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Hydroxychloroquine + Azithromycin	Hydroxychloroquine	Relative (95% CI)	Absolute (95% CI)	
All-cause mortality											
2 [1,2]	randomised trials	serious [a]	not serious	not serious	not serious	none	74/454 (16.3%)	68/431 (15.8%)	**RR 0.87** (0.44 to 1.71)	**21 fewer per 1.000** (from 88 fewer to 112 more)	⊕⊕⊕◯ MODERATE
Number of patients with any adverse events											
1 [2]	randomised trials	serious [b]	not serious	not serious	not serious	none	82/217 (37.8%)	74/221 (33.5%)	**RR 1.13** (0.88 to 1.45)	**44 more per 1.000** (from 40 fewer to 151 more)	⊕⊕⊕◯ MODERATE
Number of patients with serious adverse events											
2 [1,2]	randomised trials	serious [a]	not serious	not serious	not serious	none	105/458 (22.9%)	77/419 (18.4%)	**RR 1.12** (0.89 to 1.41)	**22 more per 1.000** (from 20 fewer to 75 more)	⊕⊕⊕◯ MODERATE
Length of stay in hospital											
1 [2]	randomised trials	serious [b]	not serious	not serious	not serious	none	217	221	-	SMD **0.07 higher** (0.12 lower to 0.26 higher)	⊕⊕⊕◯ MODERATE
Number of patients discharged											
2 [1,2]	randomised trials	serious [a]	very serious [c]	not serious	not serious	none	141/454 (31.1%)	128/431 (29.7%)	**RR 1.04** (0.68 to 1.59)	**12 more per 1.000** (from 95 fewer to 75 more)	⊕◯◯◯ VERY LOW
All-cause mortality (non-hospitalized patients)											
2 [3,4]	randomised trials	not serious	not serious	not serious	not serious	none	No deaths reported				⊕⊕⊕⊕ HIGH
SARS-CoV-2 clearance (non-hospitalized patients)											

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Hydroxychloroquine + Azithromycin	Hydroxychloroquine	Relative (95% CI)	Absolute (95% CI)	
2 [3, 4]	randomised trials	not serious	not serious	not serious	not serious	none	70/203 (34.5%)	85/201 (42.3%)	**RR 0.84** (0.65 to 1.09)	**68 fewer per 1.000** (from 148 fewer to 38 more)	⊕⊕⊕⊕ HIGH
Number of patients with any adverse event (non-hospitalized patients)											
1[3]	randomised trials	not serious	not serious	not serious	not serious	none	3/152 (2.0%)	6/152 (3.9%)	**RR 0.50** (0.13 to 1.96)	**20 fewer per 1.000** (from 34 fewer to 38 more)	⊕⊕⊕⊕ HIGH
Number of patients with serious adverse events (non-hospitalized patients)											
2 [3, 4]	randomised trials	not serious	not serious	not serious	not serious	none	No serious adverse event reported				⊕⊕⊕⊕ HIGH

Explanations

a. Downgraded of one level for high risk of performance bias in both studies and unclear risk of attrition bias in one study
b. Downgraded of one level for high risk of performance bias
c. Downgraded of one level for I^2=77%

References

1. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa M, et al; COALITION COVID-19 Brazil II Investigators. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020 Oct 3;396(10256):959-967. doi: 10.1016/S0140-6736(20)31862-6. Epub 2020 Sep 5.
2. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Jul 23:NEJMoa2019014. doi: 10.1056/NEJMoa2019014. Epub ahead of print.
3. Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle PV, Thomas CE, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine. 2020 Dec;29:100645. doi: 10.1016/j.eclinm.2020.100645. Epub 2020 Nov 20.
4. Johnston C, Brownc ER, Stewart J, Stankiewicz Karita HC, Kissinger PJ, Dwyerk J, et al., Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine 2021, https://doi.org/10.1016/j.eclinm.2021.100773